Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained a drug registration certificate for its Oseltamivir Phosphate for Suspension from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.
The drug is used for the treatment of influenza A and B in patients aged two weeks or more.